Participants 35 120 6
previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010)
Participants 363 449 5
patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Participants 482 558 6
open-label, phase 2/3 study at 202 academic medical centres in 24 countries.
Participants 559 671 6
Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells
Participants 1279 1345 8
Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients:
Participants 3177 3263 4
patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
